Dihydroindane carboxylic and cyclohexadiene acetic acids, esters and salts

ABSTRACT

Fluoro, phenyl substituted cyclohexadiene compounds of FIGS. I and II   wherein R is selected from the group consisting of hydrogen, alkyl of from one to three carbon atoms, inclusive, and a pharmaceutically acceptable metal or amine cation; X is selected from the group consisting of -CH3 and -CH2CH2with the proviso that -CH2 is attached to the 2 carbon atom of the cyclohexadiene, thereby forming an indane type compound and compositions thereof useful as an anti-inflammatory, analgesic, anti-pyretic, anti-allergic, anti-thrombolytic and inhibitor of prostaglandin synthesis.

United States Patent [191 Hall et a1.

[ Dec.3,1974

1 1 DIHYDROINDANE CARBOXYLIC AND CYCLOHEXADIENE ACETIC ACIDS, ESTERS AND SALTS [75] Inventors: Charles M. Hall; William J.

Wechter, both of Kalamazoo, Mich.

[73] Assignee: The Upjohn Company, Kalamazoo,

Mich.

22 Filed: Feb. 16, 1973 21 Appl. No.: 333,395

[52] U.S. Cl. 260/2472 R, 260/268, 260/469, 260/50l.15, 260/50l.l7, 260/515 A,

[51] Int. Cl. C07c 63/50, C070 69/76 [58] Field of Search 260/515 A, 469, 247.2

[56] References Cited UNITED STATES PATENTS 9/1969 Ka1tenbronn 260/515 2/1971 Juby et a1. 1/1973 Hamilton 260/515 Primary Examiner-James A. Patten Attorney, Agent, or Firm-Martin B. Barancik; Roman Saliwanchik 5 7 ABSTRACT Fluoro, phenyl substituted cyclohexadiene compounds of FIGS. 1 and ll wherein R is selected from the group consisting of hydrogen, alkyl of from one to three carbon atoms, in- .clusive, and a pharmaceutically acceptable metal or amine cation;

X is selected from the group consisting of CH;, and CH Cl-I with the proviso that CH is attached to the 2 carbon atom of the cyclohexadiene, thereby forming an indane type compound and compositions thereof useful as an anti-inflammatory, analgesic, anti-pyretic, anti-allergic, anti-thrombolytic and inhibitor of prostaglandin synthesis.

, I 5 Claims, No Drawings BRIEF DESCRIPTION OF THE INVENTION In accordance with this invention there are the fluoro, phenyl substituted cyclohexadiene compounds of FIGS. I and II 6 CORR tags wherein R is selected from the group consisting of hydrogen, alkyl of from one to three carbon atoms, inclusive, and a pharmaceutically acceptable metal or amine cation;

X is selected from the group consisting of CH:, and CH CH with the proviso that -CH is attached to the two carbon atom of the cyclohexadiene, thereby forming an indane type compound.

Another aspect of the invention is the pharmaceutical composition having a compound of the invention as an active ingredient.

The compounds are useful as anti-inflammatory, analgesic or anti-pyretic agents, as an anti-allergy agent, as an anti-thrombolytic agent, and as an inhibitor of 'prostaglandin synthesis.

DETAILED DESCRIPTION OF THE INVENTION As employed in the above disclosure and throughout the specification, the term alkyl includes methyl, ethyl, propyl, and isopropyl when limited to three carbon atoms. The term a pharmaceutically acceptable metal or amine cation includes alkali metals such as sodium and potassium, alkaline earth metals such as calcium and magnesium, and other acceptable metals such as aluminum and amine cations. The term amine cation includes all pharmaceutically acceptable amine cations, including, for example, cations of ammonia, tris(hydroxymethyl)amino-methane, D-threo-2-aminol-p-nitrophen-yl-l ,3-propanediol, N,N- bis(hydroxyethyl)piperazine, 2-amino-2-methyll propanol, 2-amino-2-methyl-l,3-propanediol, 2,2-

the 6-fluoro-5-phenyl-4,7-dihydroindanel-carboxylic acid isomers are separated by high pressure liquid chromatography and isolated.

In a similar manner, the a-methryl-S-fluoro-4-phenylcyclohexa-2,5-diene-l-acetic acid and a-rnethyl-5- fluoro-4-phenyl-cyclohexa-l,4-diene-l-acetic acid isomers are prepared from a-methyl-2-fluoro-4-biphenylacetic acid.

The esters or pharmaceutically acceptable metal or amine salts are prepared from the acid by standard methods.

The compounds of this invention can be administered in effective non-toxic quantities for the treatment of inflammatory conditions such as arthritis and for the treatment of pain and pyretic conditions.

The compounds can be used in the therapeutic or prophylactic treatment of allergy such as combatting the effects of an asthma attack or in prevention of an asthma attack. Its anti-thrombolytic activity is effective in situations wherein prevention of clot formation is important such as following surgery so as to prevent postoperative thrombosis, preventing transcient cerebral ischemic attacks in geriatric patients, and prophylactic treatment following myocardial infarcts and strokes.

In use, the compounds of the invention are administered in formulationstwhich comprise a compound of the invention in association with pharmaceutical excipients known for the production of compositions for oral, rectal or parenteral administration. These compositions preferably contain 01-90 percent by weight of a compound of the invention.

Compositions for oral administration are the preferred compositions of the invention, andthese are the conventional pharmaceutical forms for such administration, such as, for example, tablets, capsules, pills, powders, effervescent granules, elixirs, syrups and aqueous and oil dispersions. The excipients used in the preparation of these compositions are the excipients knownin the pharmacists art. Thus in the preparation of tablets, typical excipients include disintegrating agents, e.g., corn starch and lubricating agents, e.g.,

magnesium stearate; in the preparation of capsules, standard gelatin capsules may be used containing the active ingredient alone or admixed with a diluent. The liquid compositions may comprise as excipients water and sucrose to provide syrups, water, dispersing agents and suspending agents, e.g., methylcellulose to provide aqueous suspensions, and a non-toxic oil, e. g., a vegetable oil such as peanut oil and a suspending agent to provide oily suspensions.

We claim: 1. A compound selected from the group consisting of COR COZR and I 3. V V 6-Flu0ro- 5-phenyl-4,7-dihydroindane-lcarboxylic acid and its pharmaceutically acceptable salts according to claim 1.

4. a-Methyl-5-fluoro-4-phenyl-cyclohexa-2,4-dienel-acetic acid and its pharmaceutically acceptable salts according to claim 1.

5. a-Methyl-S-fluoro-4-phenyl-cyclohexa-1 ,4-dienel-acetic acid and its pharmaceutically acceptable salts according to claim 1. 

1. A COMPOUND SELECTED FROM THE GROUP CONSISTING OF
 2. 6-Fluoro-5-phenyl-5,7 Alpha -dihydroindane-1-carboxylic acid and its pharmaceutically acceptable salts according to claim
 1. 3. 6-Fluoro-5-phenyl-4,7-dihydroindane-1-carboxylic acid and its pharmaceutically acceptable salts according to claim
 1. 4. Alpha -Methyl-5-fluoro-4-phenyl-cyclohexa-2,4-diene-1-acetic acid and its pharmaceutically acceptable salts according to claim
 5. Alpha -Methyl-5-fluoro-4-phenyl-cyclohexa-1,4-diene-1-acetic acid and its pharmaceutically acceptable salts according to claim 